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CytokineInﬂammatory cytokines have a signiﬁcant role in altering the innate and adaptive arms of immune responses.
Here, we analyzed the effect of GM-CSF on a RABV-vaccine vector co-expressing HIV-1 Gag. To this end, we
immunized mice with RABV expressing HIV-1 Gag and GM-CSF and analyzed the primary and recall CD8+ T
cell responses. We observed a statistically signiﬁcant increase in antigen presenting cells (APCs) in the spleen
and draining lymph nodes in response to GM-CSF. Despite the increase in APCs, the primary and memory anti
HIV-1 CD8+ T cell response was signiﬁcantly lower. This was partly likely due to lower levels of proliferation
in the spleen. Animals treated with GM-CSF neutralizing antibodies restored the CD8+ T cell response. These
data deﬁne a role of GM-CSF expression, in the regulation of the CD8+ T cell immune responses against RABV
and has implications in the use of GM-CSF as a molecular adjuvant in vaccine development.
© 2012 Elsevier Inc. All rights reserved.Introduction
More than 30 years after the discovery of human immunodeﬁciency
virus 1 (HIV-1), there are still no promising vaccine approaches. This is
in part due to the fact that the correlates of protection againstHIV-1 infec-
tion or AIDS are still not very well deﬁned. However, the assessment of
long-term progressors infected with HIV indicates that CD8+ T cells
play an important role in controlling the virus (Borrow et al., 1994).
Moreover, depletion of CD8+ T cells in rhesus macaques infected with
simian immunodeﬁciency virus (SIV) led to an increase in viral RNA in
their plasma (Jin et al., 1999). As such, there have been efforts to improve
themagnitude and quality of CD8+ T cell responses in addition to the hu-
moral immune responses. Live attenuated viral vectors are efﬁcient at in-
ducing both cellular and humoral immune responses because i) they are
able to replicate in vivo, providing antigens that can be processed andpre-
sented on MHC I and MHCII, and ii) most viral vectors are recognized by
pattern recognition receptors (PRR) throughwhich they initiate signaling
cascades, consequently expressing inﬂammatory cytokines thatmay pro-
vide a strong third signal for antigen presenting cells (APCs) (for review:
Iwasaki and Medzhitov, 2004; Kindt et al., 2007).
Rabies virus (RABV) is a single stranded negative-sense RNA virus
of the Rhabdoviridae family. It has a modular genome that encodes
ﬁve genes (Schnell et al., 2010) and can be easily manipulated to. 10th Street BLSB Room 531,
. Schnell).
mmunology, University of Cal-
rights reserved.include multiple foreign genes that can be stably expressed over at
least twenty viral passages (Mebatsion et al., 1996). As such RABV-
based vaccine vectors have been developed and tested in mice and
non-human primates (NHPs) for more than a decade (Cenna et al.,
2009; Faul et al., 2008, 2009; Gomme et al., 2010; McGettigan et al.,
2003a, 2006; Wanjalla et al., 2010). A number of these studies have
established that RABV vaccine vectors expressing HIV/SIV can induce
potent antigen-speciﬁc CD8+ T cell responses (Faul et al., 2009;
Gomme et al., 2010; Wanjalla et al., 2010). Furthermore, NHPs immu-
nized with RABV vaccine vectors expressing SIVMac239 GagPol and
SIVMac239 Env were protected from an AIDS-like disease after chal-
lenge with SIVMac251 (Faul et al., 2009).
Attempts to improve RABV vaccine vector performance have in-
cluded the co-expression of molecular adjuvants and HIV-1 proteins.
The ﬁrst study showed that the anti-HIV humoral response could be
enhanced using a RABV vaccine vector co-expressing interleukin 2
(IL-2). Interleukin 4 (IL-4) expression on the other hand did not im-
prove the humoral response, while it decreased the CD8+ T cell re-
sponse (McGettigan et al., 2006). This was followed by a study in
which interferon-β (IFN-β) was expressed along with HIV-1 Gag
both encoded in a RABV vaccine vector. This increased the primary
CD8+ T cell response despite a signiﬁcant decrease in viral replication
due to the direct anti-viral effects of type I IFN (Faul et al., 2008). Al-
though there was an increase in the primary CD8+ T cell response, no
increase was seen during the memory phase and the CD8+ T cell cy-
tokine proﬁles were not different from the proﬁles of control animals
(Faul et al., 2008). Of note, none of the cytokines that have been in-
cluded in the RABV vaccine vectors against HIV-1 showed an im-
provement of both cellular and humoral immune responses.
121C.N. Wanjalla et al. / Virology 426 (2012) 120–133GM-CSF is a hematopoietic cytokine ﬁrst isolated from lung tissue
(Burgess et al., 1977) and later described as a growth factor required
for the generation of granulocytes and macrophages (Metcalf, 1985).
Additional studies further elaborated on its role in the proliferation
and differentiation of dendritic cells (DCs) (Inaba et al., 1992). In
vivo, GM-CSF is constitutively expressed by ﬁbroblasts, endothelial
cells, activated T cells, monocytes or macrophages, (Burgess et al.,
1977) and can act on a number of cells including monocytes, lympho-
cytes, granulocytes, macrophages and endothelial cells, which are
known to express the receptor (Parmiani et al., 2007). Despite these
important functions, mice lacking the GM-CSF receptor or GM-CSF
expression are viable and in fact have insigniﬁcant defects in the he-
matopoietic compartment compared to wildtype mice (Stanley et al.,
1994), implicating redundancy with other growth factors. Of note,
GM-CSF expression in healthy mice is present at low undetectable
levels in the serum and is often transiently expressed in the course
of some infections after which it is degraded or taken up via high af-
ﬁnity receptors (Metcalf et al., 1999). There are a few conditions thata
c e
b
Fig. 1. Plasmid construction and characterization of viral constructs. The RABV vaccine vect
and BNSP-Gag–GM-CSF (iv) is the experimental vaccine being analyzed here (a). BSR cells i
stained for internal expression of RABV-N and HIV-1 Gag (b). The growth kinetics of the diff
of the viral vectors was also monitored by quantiﬁcation of RABV-N mRNA in the muscles o
and secretion was monitored by a quantitative ELISA of supernatants 24, 48 and 72 h posthave been shown to induce signiﬁcant levels of GM-CSF detectable in
the serum, such as LPS (Metcalf, 1971).
GM-CSF was ﬁrst used as a vaccine adjuvant in a hepatitis B vac-
cine and shown to improve responsiveness to the vaccine in more
than half of previous non-responders (Carlsson and Struve, 1997).
Since then other studies have shown the efﬁcacy of GM-CSF as a vac-
cine adjuvant in mice (Lu et al., 2002; Wen et al., 2010; Yoon et al.,
2006; Zhang et al., 2011) and NHP (Loudon et al., 2010). The use of
GM-CSF has even extended to human clinical trials in which it has
been used as an efﬁcient adjuvant in cancer vaccines (Jaffee et al.,
2001; Luiten et al., 2005; Mastrangelo et al., 1999). Whereas majority
of the studies in which GM-CSF has been used include DNA, peptide
or cell-based vaccines, immunostimulatory effects of GM-CSF have
been seen with several viral vectors including, adenovirus (Lu et al.,
2002), vesicular stomatitis virus (VSV) (Ramsburg et al., 2005), retro-
viruses (Dranoff et al., 1993) and vaccinia virus (VV) (Kass et al.,
2000; Mastrangelo et al., 1999). More recently, a RABV vector expres-
sing GM-CSF enhanced vector-speciﬁc humoral responses due toors used throughout this study are illustrated: viruses (i)–(iii) will be used as controls
nfected with BNSP, BNSP-Gag–IFN(−) and BNSP-Gag–GM-CSF for 48 h were ﬁxed and
erent viruses were monitored on BSR cells after infection at MOI of 0.01 (c). Replication
f immunized mice (n=4 for each group) 3 days post infection (d), GM-CSF expression
infection at an MOI=10 (e).
122 C.N. Wanjalla et al. / Virology 426 (2012) 120–133recruitment/activation of a signiﬁcant number of DCs and B cells
(Wen et al., 2010).
On the contrary, there is evidence that GM-CSF can suppress im-
mune responses through recruitment of myeloid suppressor cells,
which can mediate suppression by activating regulatory T cells
(Tregs). Such effects have been associated with high levels of GM-
CSF expression. Mice immunized with autologous tumor cells as the
source of antigen combined with increasing doses of a bystander
cell line as the source of GM-CSF, showed that GM-CSF was effective
as an adjuvant over a range of doses but there was a threshold
above which it became immunosuppressive. The high doses recruited
myeloid derived suppressor cells that impaired antigen speciﬁc im-
mune responses (Seraﬁni et al., 2004). Another mechanism of im-
mune suppression is via direct stimulation of Tregs which express a
functional GM-CSF receptor downstream of which they are activated
to expand independent of IL-2 (Kared et al., 2008).
The recent data showing improved humoral responses to a RABV
vaccine vector expressing GM-CSF (Wen et al., 2010), suggested
that addition of this cytokine to a RABV-vaccine vector against HIV-
1 Gag has the potential to improve both cellular and humoral immune
responses. We show that GM-CSF alters the immune response to
RABV. Expression of GM-CSF clearly increased the APCs in the drain-
ing LNs and spleens. On the other hand, there were signiﬁcantly
fewer antigen speciﬁc CD8+ T cells in the presence of GM-CSF.a GMCSF(+)
1:7
GMCSF(+)
1:4
rG
10
c
Fig. 2. BNSP-Gag–GM-CSF expresses biologically functional GM-CSF. To test the biological ac
plemented with either 10 ng/ml recombinant GM-CSF or UV-inactivated supernatants from
in media. After 7-day culture, the cells were harvested and stained with antibodies against C
(for a total n=6).Immunization of mice with the same vector in the presence of GM-
CSF neutralizing antibodies conﬁrmed that the regulation of the
CD8+ T cell response was dependent on GM-CSF expression. This
study highlights a role of GM-CSF in regulating immune responses
to RABV vaccine vector and could have implications on the use of
GM-CSF as a vaccine adjuvant.
Results
Cloning and characterization of vaccine constructs
The recombinant RABV vaccine vectors, BNSP and BNSP expres-
sing HIV-1 Gag (BNSP-Gag) have been described previously
(McGettigan et al., 2003b). For this study, we cloned the gene encod-
ing mouse GM-CSF gene into the BNSP-Gag vector between G and L
genes resulting in BNSP-Gag–GM-CSF. A similar vector co-
expressing HIV-1 Gag and a non-functional (ATG deleted) IFN-β
gene (Faul et al., 2009) served as a control vector for the experiments
(Fig. 1a). The virus was recovered by standard methods and viral
stocks were prepared as described previously (Faul et al., 2008;
McGettigan et al., 2001). We conﬁrmed expression of HIV-1 Gag by
infecting BSR cells (a BHK clone) with BNSP, BNSP-Gag–IFN(−) or
BNSP-Gag–GM-CSF in duplicate. Forty-eight hours later, one well of
each RABV vector was stained with antibodies against RABV-NMCSF
ng/ml
b
tivity of the secreted GM-CSF, primary bone marrow cells were cultured in media sup-
BNSP-Gag–IFN(−) and BNSP-Gag–GM-CSF(+) infected BSR cells diluted at 1:7 or 1: 4
D11c (a–c), CD80 and CD86 (c). The data are representative of two repeat experiments
123C.N. Wanjalla et al. / Virology 426 (2012) 120–133protein to conﬁrm infection (Fig. 1b, top panels). HIV-1 Gag expres-
sion was conﬁrmed in the duplicate wells using a human monoclonal
antibody against p24, followed by a Cy2-tagged donkey anti human
IgG secondary antibody (Fig. 1b, bottom panel).
To determine whether the insertion of HIV-1 Gag and GM-CSF
changed the growth kinetics of the vaccine vector, we infected BSR
cells at an MOI of 0.01 as described in Materials and methods. We
then collected supernatants from the infected cells at different times
points. Viral titers in the supernatant were quantiﬁed to generate
the multi-step growth curve (Fig. 1c). There were no differences be-
tween BNSP-Gag and BNSP-Gag–IFN(−) whereas BNSP-Gag–GM-
CSF grew approximately half a log lower. As previously described,
the BNSP vector grew one log higher than BNSP-Gag because it does
not contain additional genes. Due to the apparent albeit slight differ-
ence between BNSP-Gag–IFN(−) and BNSP-Gag–GM-CSF, we also
analyzed the in vivo replication kinetics of the three Gag-expressing
vaccine vectors to ensure that they were similar in replication and
spread. The amount of viral messenger RNA in each mouse showed
no statically signiﬁcant difference between BNSP-Gag–IFN(−) and
BNSP-Gag–GM-CSF (Fig. 1d).
Following infection of BSR cells with BNSP-Gag–IFN(−) or BNSP-
Gag–GM-CSF, GM-CSF expression was quantiﬁed by ELISA over a
72 h period (Fig. 1e). The biological functionality of the GM-CSF was
tested by its ability to differentiate bone marrow cells (BM) into
DCs (Inaba et al., 1992). Supernatants from BSR cells that had been
infected with BNSP-Gag–IFN(−) or BNSP-Gag–GM-CSF were UV-
inactivated to kill any live RABV. UV-inactivated supernatant or0
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Fig. 3. BNSP-Gag–GM-CSF expresses GM-CSF that has physiological effects on DCs in vivo. 6
Gag–IFN(−) or BNSP-Gag–GM-CSF. 3 days later the spleens, draining lymph nodes and bloo
and CD11b (a) and activation marker — CD86 and CD11c (b). Statistical analysis was perfo
obtained by t-test whereas P values indicated by * were obtained by one-way ANOVA test.recombinant GM-CSF was added to primary BM cell cultures. BNSP-
Gag–GM-CSF supernatant was able to differentiate primary BM cells
into CD11c+ DCs (Figs. 2a–b). In comparison to the DCs generated
with recombinant GM-CSF, supernatant from BNSP-Gag–GM-CSF
generated fewer CD11c+ cells. In addition, more of the CD11c+ cells
generated following BNSP-Gag–GM-CSF supernatant treatment had
a mature phenotype based on CD80+ and CD86+ expression
(Fig. 2c). As expected, the BM cells cultured in media supplemented
with BNSP-Gag–IFN(−) supernatants were not viable by day 7 of
culture (Figs. 2b and c). Taken together these results indicated that
BNSP-Gag–GM-CSF expressed both HIV-1 Gag and GM-CSF that was
capable of differentiating BM cells into DCs.
GM-CSF expression by RABV signiﬁcantly increases the number of
professional antigen presenting cells in vivo
Presentation of antigens is purported to be important in the induc-
tion of immune responses against viral infections including rabies
virus (Plesa et al., 2006). We next determined the impact of GM-CSF
expression on antigen presenting cells in vivo. 6–8 week old BALB/c
mice were immunized with BNSP-Gag, BNSP-Gag–IFN(−), BNSP-
Gag–GM-CSF or PBS and FACS analysis was performed three days
post immunization. In comparison to PBS controls, all three RABV
vaccine vectors induced a signiﬁcantly higher number of CD11c+
CD11b+ (Fig. 3a) and CD11c+ CD86+ (Fig. 3b) cells in the blood.
Within immune compartments, namely the spleen and draining
inguinal LNs, immunization with BNSP-Gag–GM-CSF resulted in aag
-IF
N(-
)
BN
SP
-G
ag
-G
M-
CS
F
PB
S
BN
SP
-G
ag
BN
SP
-G
ag
-IF
N(-
)
BN
SP
-G
ag
-G
M-
CS
F
ag
-IF
N(-
)
BN
SP
-G
ag
-G
M-
CS
F
PB
S
BN
SP
-G
ag
BN
SP
-G
ag
-IF
N(-
)
BN
SP
-G
ag
-G
M-
CS
F
0.0847
*
63
L LYMPH
DE
BLOOD
Pe
rc
en
ta
ge
 o
f C
D1
1c
+ 
CD
11
b+
 c
el
ls
0
1
2
3
0.0735
0.0871
Pe
rc
en
ta
ge
 o
f C
D1
1c
 C
D8
6+
 c
el
ls
0
1
2
3
0.0515
0.0188
0.0374
–8 week old BALB/c mice were immunized with 1×105 FFU of either BNSP-Gag, BNSP-
d were harvested and stained with antibodies against surface markers of DCs — CD11c
rmed using one-WAY ANOVA and Student's t-tests. Numerical statistical values were
*Pb0.05, **Pb0.01.
124 C.N. Wanjalla et al. / Virology 426 (2012) 120–133signiﬁcantly higher number of CD11c+ CD11b+ DCs compared to
BNSP-Gag and BNSP-Gag–IFN(−) (Fig. 3a). No differences were
seen in the number of CD11c+ CD11b+ and CD11c+ CD86+
measured in the muscle (data not shown). In addition to DCs,
macrophages also have a signiﬁcant role in antigen presentation
and have been implicated to play a role in both direct and cross
presentation of antigens (Brode and Macary, 2004). As with DCs,
GM-CSF expression by the RABV vaccine vector increased the number
of CD11b+ F480+ macrophages and activated CD19+ CD40+ B cells
(Fig. S1). Taken together, the data show that the exogenous GM-CSF
is expressed at physiologically active levels in vivo resulting in a sig-
niﬁcant increase of antigen presenting cells.
Analysis of vector speciﬁc humoral response
It was recently shown that GM-CSF expression by a RABV vaccine
vector increased the virus directed neutralizing antibody titer in com-
parison to mice immunized with just the vector (Wen et al., 2010).
However, the authors did not provide any data on the total IgG titers
or isotypes.
In order to characterize the humoral immune response to the
RABV vaccine vector, we obtained blood from mice used in the chal-
lenge experiments, 35 days post prime with 105 FFU of either BNSP-
Gag–IFN(−), BNSP-Gag–GM-CSF or PBS. We did not observe
differences in the anti-RABV-G IgG titers (Fig. S2a) or in the IgG1
and IgG2a titers. In fact, both vaccine regimens had a Th1 skewed im-
mune proﬁle, IgG2a: IgG1>1 (Fig. S2b). We also performed avidity
assays, again with no apparent differences 35 days post prime be-
tween the GM-CSF expressing vector and controls (Fig. S2c). An
RFFIT assay showed no differences in the VNA titers between ourc
d
a b
Fig. 4. Analysis of the magnitude of Gag-speciﬁc CD8+ T cells in the draining lymph nodes. 6–
BNSP-Gag–GM-CSF. PBS mice were included as a negative control. The draining inguinal lym
of CD8+ T cell markers was gated as shown (b). The quantity of Gag-speciﬁc cells was measu
speciﬁc CD8+ T cells were gated on CD62Llo cells (d). To further measure the functionality
using one-way ANOVA and t-test.control vector BNSP-Gag–IFN(−) and the experimental BNSP-Gag–
GM-CSF. Based on these data, we conclude that GM-CSF expressed
by RABV did not alter the humoral immune response.
GM-CSF expression by a recombinant RABV vector induces disparate
effects on the primary CD8+ T cell proﬁle in the draining lymph
nodes and spleen
The increase in the number of antigen presenting cells after GM-
CSF expression could augment the CD8+ T cell response induced by
RABV, as has been shown for other negative single stranded RNA vi-
ruses, such as NDV and VSV (Janke et al., 2007; Ramsburg et al.,
2005). To test this hypothesis, we immunized mice with 1×105 FFU
BNSP-Gag, BNSP-Gag–GM-CSF, or BNSP-Gag–IFN(−) and over time
monitored the primary Gag-speciﬁc CD8+ T cell response in the
draining ILNs (Fig. 4a) and spleens (Fig. 4a). Once cells were har-
vested they were stained and analyzed by FACS. All cells analyzed
were ﬁrst gated for CD8 expression and activation (CD62L). Activated
CD8+ CD62Llo T cells were further analyzed for Gag antigen
(AMQMLKETI) speciﬁcity (Figs. 4b and 5b).
We detected Gag-speciﬁc CD8+ T cells with all three recombinant
RABV constructs in the ILNs (Figs. 4c–d) and spleen (Figs. 4c–d) as
early as 7 days after immunization. By day 10, there were no statisti-
cally signiﬁcant differences in the magnitude of Gag-speciﬁc CD8+ T
cells in the draining ILNs, although there was a trend towards higher
numbers in the GM-CSF group. Similarly, there were no differences in
the functionality of the activated Gag-speciﬁc cells (Fig. 4f). On the
other hand, in the spleen we observed that GM-CSF expression de-
creased the number of Gag-speciﬁc CD8+ T cells over time. By day
10, mice immunized with BNSP-Gag–GM-CSF had signiﬁcantlyf
e
8 week old BALB/c mice were primed with 1×105 FFU BNSP-Gag, BNSP-Gag–IFN(−) or
ph nodes were isolated from mice on days 3, 7, 10 and 16 (a). Flow cytometry analysis
red with a tetramer stain against H2d restricted AMQMKLETI epitope (c). Activated Gag-
of the cells, an IFN-γ ELISpot assay was done (e–f). Statistical analysis was performed
125C.N. Wanjalla et al. / Virology 426 (2012) 120–133fewer Gag-speciﬁc CD8+ T cells than BNSP-Gag immunized mice in
the spleen (Figs. 5c–d). Of note, the results are represented as per-
centages as previously published (Faul et al., 2008; Gomme et al.,
2010). We also analyzed the total numbers of Gag-speciﬁc CD8+ T
cells in the spleens and draining ILNs and obtained results that corre-
lated with the percentage data (data not shown). Furthermore, func-
tional expression of IFN-γ as monitored by ELISpot aligned with the
magnitude of Gag-speciﬁc CD8+ T cells detected by tetramer staining
(Fig. 5f). Taken together, the analysis of the primary immune re-
sponse indicated that GM-CSF expression by RABV signiﬁcantly re-
duces the Gag-speciﬁc CD8+ T cell responses in the spleen.
GM-CSF expression reduces the memory CD8+ T cell response
Although the primary immune response to a vaccine is a predictor
of the recall response, the generation of memory cells and their ex-
pansion after re-exposure to HIV-1 Gag was also evaluated. To ana-
lyze the memory cells, BALB/c mice were primed i.m. with the three
RABV vaccine vectors or PBS and analyzed for Gag-speciﬁc CD8+ T
cells 30 days later. Similar to what has been detected in the primary
immune response, GM-CSF expression did not alter the generation
of long-lived Gag-speciﬁc CD8+ T cells in the ILNs (Fig. 6a), but signif-
icantly lowered numbers of Gag-speciﬁc CD8+ T memory cells in the
spleen (Figs. 6b and c).
In order to analyze the expansion of the HIV-1 Gag-speciﬁc mem-
ory CD8+ T cells after challenge, we infected mice with recombinant
vaccinia virus expressing HIV-1 Gag (VV-Gag) 30 days after the orig-
inal immunization. Immune responses were analyzed 3, 4 and 5 days
post challenge by FACS and ELISpot (Fig. 7a). Similar to what was seen
when observing resting memory CD8+ T cells, mice immunized withd 
b a 
c 
D3     7     10    16       
Fig. 5. GM-CSF expression reduces the magnitude of the Gag-speciﬁc CD8+ T cells in the sp
IFN(−) or BNSP-Gag–GM-CSF. PBS mice were included as a negative control. The spleens w
T cell markers was gated as shown (b). The quantity of Gag-speciﬁc cells was measured
speciﬁc CD8+ T cells were gated on CD62Llo cells (d). To further measure the functionality
using one-way ANOVA *Pb0.05, **Pb0.01.BNSP-Gag–GM-CSF had a signiﬁcantly fewer Gag-speciﬁc CD8+ T
cells in the spleen days 3 post challenge (Fig. 7c), while no difference
was detected in the draining ILNs of the same mice (Fig. 7b). Analysis
of functional expression of IFN- γ corresponded with the magnitude
of AMQMKLETI+ CD8+ T cells (Fig. 7d). Based on these ﬁndings,
GM-CSF expression by RABV reduces the Gag-speciﬁc CD8+ T cells
in the spleen.
Due to the disparity of the primary Gag-speciﬁc CD8+ T cell re-
sponse in the ILNs and spleens, we were concerned that an i.p. chal-
lenge with VV-Gag biased the HIV-1 Gag speciﬁc cell expansion in
the spleen. Furthermore, there is a possibility that GM-CSF expression
alters the distribution of Gag-speciﬁc CD8+ T cells to different organs
including LNs, spleen and muscle. In order to generate a recall re-
sponse reﬂective of the memory cells present in the draining ILNs
we challenged mice either subcutaneously distal to the popliteal
lymph node (PLN) to target the lymphatic system (Figs. 8c–d) or in-
tramuscularly (Figs. 8a–b) to target the muscle tissue and draining
ILNs. Similar to i.p. challenge, animals that were immunized with
BNSP-Gag–GM-CSF and challenged with VV-Gag subcutaneously or
intramuscularly had signiﬁcantly fewer Gag-speciﬁc CD8+ T cells in
all lymphoid organs analyzed, most apparent in the spleen and PLNs
(Figs. 8a and c). We also analyzed expression of inﬂammatory cyto-
kines by the CD8+ T cells in the spleens and popliteal lymph nodes.
We observed that upon stimulation with the HIV-1 Gag-speciﬁc
AMQMKLETI peptide, the CD8+ T cells expressed IFN-γ, TNF-α, IL2,
IL6 and IL10 proportional to the magnitude of the Gag-speciﬁc
CD8+ T cell response, indicating further that GM-CSF expression re-
duces just the number of Gag-speciﬁc CD8+ T cells but not their qual-
ity (Figs. 8b and d). In addition, experiments in which in vitro
cytotoxic T lymphocyte assays were performed with CD8+ T cellse 
f 
leen. 6–8 week old BALB/c mice were primed with 1×105 FFU BNSP-Gag, BNSP-Gag–
ere isolated from mice on days 3, 7, 10 and 16 (a). Flow cytometry analysis of CD8+
with a tetramer stain against H2d restricted AMQMKLETI epitope (c). Activated Gag-
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aPB
S
BN
SP
-G
ag
BN
SP
-
Ga
g-I
FN
(-)
BN
SP
-G
ag
-G
M-
CS
F
0.0
0.1
0.2
0.3
0.4
%
 A
M
QM
LK
ET
I+
 
CD
8+
T 
Ce
lls
 
*
Lymph node
PB
S
BN
SP
-
Ga
g
BN
SP
-
Ga
g-I
FN
(-)
BN
SP
-G
ag
-G
M-
CS
F
0.0
0.2
0.4
0.6
0.8
%
 
A
M
QM
LK
ET
I+
 
CD
8+
T 
Ce
lls
 
*
**
Spleen
b c
Fig. 6. Reduction of CD8+ T cells by GM-CSF expression persists into the memory phase. BALB/c mice were immunized i.m. with 1×105 FFU BNSP-Gag, BNSP-Gag–IFN(−) or
BNSP-Gag–GM-CSF and rested for 30 days at which point the ILNs and spleen was harvested. Gag-speciﬁc CD8+ T cells were quantiﬁed by ﬂow cytometry in the draining
ILNs (a) and spleen (b). Secretion of IFN-γ by AMQMKLETI peptide pulsed cells was measured in an ELISpot assay (c). Statistical analyses were performed using one-way
ANOVA, *Pb0.05, **Pb0.01.
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correlation between cell lysis and the magnitude of the Gag-speciﬁc
CD8+ T cell response (data not shown). Furthermore, there were no
differences in the avidity of the CD8+ T cells (data not shown).
In summary, all three different routes of challenge consistently
showed a lower memory and recall Gag-speciﬁc CD8+ T cell re-
sponse in mice immunized with the GM-CSF expressing virus. In ad-
dition, there were no differences in the quality of the CD8+ T cells
monitored by analysis of inﬂammatory cytokines expressed upona
c
D30  33 34 35      
PBS
BNSP-Gag-IFN(-)
BNSP-Gag-GM-CSF
VV-Gag
Fig. 7. Mice challenged i.p. with VV-Gag elicit a recall response proportional to the primary
Gag–IFN(−) and BNSP-Gag–GM-CSF were rested for 30 days. Each group was challenged wi
lenge as shown (a). Gag-speciﬁc CD8+ T cells in the lymph nodes (b) and spleen (c) were an
further monitored in an IFN-γ ELISpot assay following AMQMKLETI peptide stimulation (d).
are representative of three repeat experiments.activation by a Gag-speciﬁc antigen. Although results from these ex-
periments indirectly addressed whether GM-CSF altered the distri-
bution of Gag-speciﬁc CD8+ T cells, further studies looking at the
distribution of CD8+ T cells post prime are required. One challenge
with such experiments is that there will be likely only a very low
number of antigen speciﬁc CD8+ T cells after priming in organs
other than the secondary lymphoid organs which would make it
challenging for quantiﬁcation, probably requiring pooling of samples
from individual mice.d
b
and memory immune proﬁles in the spleen. Mice immunized with 1×105 FFU BNSP-
th 1×106 FFU VV-Gag and the immune responses analyzed on days 3, 4 and 5 post chal-
alyzed and presented as a percentage. The functional expression of the CD8+ T cells was
Statistical analysis was performed using one-way ANOVA, *Pb0.05, **Pb0.01. The data
c d
a b Spleen PLN
Spleen PLN
Lateral tarsus - subcutaneous
Intramuscular
Fig. 8. Different routes of VV-Gag challenge do not rescue the CD8+ T cell response. BALB/c mice that had been previously immunized with 1×105 FFU BNSP-Gag (green dots),
BNSP-Gag–IFN(−) (blue dots) and BNSP-Gag–GM-CSF (red dots) were challenged either intramuscularly or subcutaneously with 1×106 FFU VV-Gag 40 days post prime. PBS
mice (black dots) were included as a negative control. 5 days post challenge, the draining inguinal lymph nodes (ILN), popliteal lymph nodes (PLN) and spleens were harvested
and the number of Gag-speciﬁc CD8+ T cells measured using AMQMKLETI tetramer staining from both the intramuscular (a) and subcutaneous (c) groups. The quality of the
CD8+ T cells was measured by intracellular cytokine staining for inﬂammatory (IFN-γ, TNF-α, IL-2 and IL-6) and inhibitory (IL-10) cytokines after stimulation of cells with AMQMK-
LETI peptide (b,d). Statistical analysis was performed using one-way ANOVA, *Pb0.05, **Pb0.01, ***Pb0.001, ****Pb0.0001.
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GM-CSF expression
Analysis of Gag-speciﬁc CD8+ T cells generated in response to the
vaccine vectors suggested that the diminished response was GM-CSF
dependent. To conﬁrm this and to rule out any impairment of the
GM-CSF expressing viral vector we performed immunizations with a
mixture of both constructs (BNSP-Gag–IFN(−) and BNSP-Gag–GM-
CSF) in a 1:1 ratio 2×105 FFU/mouse. Based on previous studies, it
has been shown that replication competent and single-cycle RABV vac-
cine vectors stimulate robust CD8+ T cell responses against HIV-1 Gag
with a similar magnitude over a range of doses 104–106, in a dose inde-
pendentmanner (Gomme et al., 2010). Thus, we hypothesized that im-
munization of mice with the mixture of both constructs
aforementioned would not change the magnitude of the Gag-speciﬁc
CD8+ T cell response if the differences between the two vectors were
due to a defect in the BNSP-Gag–GM-CSF vector. However, if the
exogenous GM-CSF was responsible for the diminished CD8+ T cell re-
sponses, then a combination of the vectors would lower the response
elicited by BNSP-Gag–IFN(−). Ten days following immunization with
the 1:1 viral mix, the Gag-speciﬁc CD8+ T cell responses were moni-
tored with an IFN-γ ELISpot assay. The combination of both vectors in-
duced a lower CD8+ T cell response than immunization with BNSP-Gag–IFN(−) alone (Fig. 9), likely due to a GM-CSF induced effect on
the Gag-speciﬁc CD8+ T cell response.
Immunization of mice with the 1:1 viral mix of BNSP-Gag–IFN(−)
and BNSP-Gag–GM-CSF suggested that the BNSP-Gag–GM-CSF
construct had a dominant negative effect on the immune response.
Although including a GM-CSF-expressing vector in trans lowered the
Gag-speciﬁc CD8+ T cell response to BNSP-Gag–IFN(−), the
response remained higher than the response to BNSP-Gag–GM-CSF
alone. In order to further conﬁrm that GM-CSF expression is respon-
sible for the reduction of Gag-speciﬁc CD8+ T cells, we treated mice
with a neutralizing antibody directed against GM-CSF one day prior
to immunization, and for another six days post prime including the
day of immunization (Fig. 10a). Ten days post prime, the Gag-
speciﬁc CD8+ T cell response was evaluated by tetramer staining
(Fig. 10b). The results indicated that treatment with anti-GM-CSF in-
creased the numbers of Gag-speciﬁc CD8+ T cells response approxi-
mately ﬁve-fold compared to untreated BNSP-Gag–GM-CSF
immunized mice determined by the functional expression of IFN-γ
in an ELISpot assay (Fig. 10c). Analyses of recall responses were
done in mice primed as above except that the control BNSP-Gag–
GM-CSF group was treated with an equal volume of PBS i.p. similar
to the anti-GM-CSF treatment group. The mice were challenged
60 days post prime with 106pfu VV-Gag i.p. and CD8+ T responses
Fig. 9. Analysis of AMQMKLETI speciﬁc CD8+ T cell induction after co-immunization
with BNSP-Gag–IFN(−) and BNSP-Gag–GM-CSF. BALB/c mice were immunized with
2×105 FFU BNSP-Gag–IFN(−), 2×105 FFU BNSP-Gag–GM-CSF or 1×105 FFU BNSP-
Gag–IFN(−)+1×105 FFU BNSP-Gag–GM-CSF. PBS mice were included as a control.
The primary immune response was monitored 10 days post prime by analysis of
CD8+ CD8+AMQMKLETI-stimulated functional expression of IFN-γ by Gag-
speciﬁc CD8+ T (a) and IL2 (b) cells were measured using ELISpot assays. Statistical
analysis was performed using one-way ANOVA *Pb0.05, **Pb0.01, ***Pb0.001.
128 C.N. Wanjalla et al. / Virology 426 (2012) 120–133analyzed 5 days later by tetramer analysis. Similar to the primary im-
mune response, anti-GM-CSF treatment effectively neutralized the
cytokine and led and higher CD8+ T cells compared to BNSP-Gag–a
c
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Fig. 10. Administration of anti-GM-CSF during immunization partially restores the CD8+ T
tralizing antibody followed by daily treatments for a total of 7 days. The primary immune re
ciﬁc CD8+ T cells was measured in the spleens of immunized mice on day 10 of the immu
Secondary Gag-speciﬁc CD8+ T cell responses were monitored after 5 days post i.p. challeng
statistical values (P) are indicated on the graphs and *Pb0.05.GM-CSF alone (Fig. 10d). Taken together, these data conﬁrm that
GM-CSF expressed by the RABV vaccine vector against HIV-1 Gag
expressing GM-CSF is responsible for the diminished Gag-speciﬁc
CD8+ T cell response.
GM-CSF expressing RABV does not negatively affect CD8+
T cell proliferation
The results obtained indicate that exogenous GM-CSF expression by
a RABV-vaccine vector against HIV-1 Gag reduces antigen-speciﬁc
CD8+ T cells. Studies in which GM-CSF has diminished immune re-
sponses have attributed the decrease to various factors downstream
of the induction of myeloid suppressor cells (MSDCs) (Vasu et al.,
2003). Reductions in CD8+ T cells by MSDCs are due to their regulation
of proliferation or apoptosis (Parmiani et al., 2007). In order to deter-
mine whether the decrease in antigen-speciﬁc CD8+ T cells seen fol-
lowing immunization with BNSP-Gag–GM-CSF can be attributed to
MSDCs, we performed ﬂow cytometry analysis of splenocytes and
lymphocytes from mice 3 days post prime. However, we observed an
insigniﬁcant induction of CD11b+ GR1+ MSDCs (data not shown).
Thus, it does not appear that MSDCs are responsible for the decreased
antigen-speciﬁc CD8+ T cell response to our vaccine.
In order to determine whether T cell proliferation was affected by
the incorporation of GM-CSF in our vaccine design, we immunized
BALB/c mice with 105 FFU of BNSP-Gag–IFN(−) or BNSP-Gag–GM-
CSF. The mice were each given 200 μl of 1 mg/ml BrdU i.p. three
days post prime, and 0.8 mg/ml BrdU in their drinking water for the
next three days. Of note, due to the relatively low frequency of Gag-
speciﬁc CD8+ T cells during the primary immune response and the
fact that the diminished CD8+ T cell responses were GM-CSF depen-
dent and not Gag-dependent, we measured BrdU incorporation in the
total activated CD62Llo CD8+ T cells. In this way, we were observing ab
d
cell response. BALB/c mice were pre-treated with 75ug anti-GM-CSF (MP1-22e9) neu-
sponse was monitored in the mice 10 days post prime (a). Analysis of AMQMKLETI spe-
ne response (b). Functional expression of IFN-γ was measured in an ELISpot assay (c).
e with VV-Gag (d). Statistical analysis was performed using Student's t-tests. Numerical
Fig. 11. BrdU proliferation assay on activated CD8+ T cells. BALB/c mice were immu-
nized with 1×105 FFU BNSP-Gag–IFN(−) or BNSP-Gag–GM-CSF. One PBS mouse was
added as a control. Three days post prime, the mice were injected i.p. with 2 mg
BrdU. For the following three days, the mice were given BrdU (0.8 mg/ml) in their
water. The spleens and ILNs were isolated from the mice 7 days post prime.
Activated CD62Llo CD8+ T cells were measured by ﬂow cytometry (a). BrdU positive
cells among the CD62Llo CD8+ T cells are shown (b). Statistical analysis was
performed using one-way ANOVA, *Pb0.05, ***Pb0.001.
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1 Gag. Mice were immunized and 7 days post prime, we obtained the
spleens and LNs for analysis by FACS and gated total activated CD8+ T
cells (Fig. 11a). There were fewer total activated CD8+ T cells in the
draining ILNs of BNSP-Gag–GM-CSF immunized mice than in the
control animals. However, these differences did not appear to be
due to differences in proliferation due to similar incorporation of
BrdU within this group of activated CD8+ T cells (Fig. 11b). Similar
analyses were done on splenocytes, which showed no signiﬁcant
differences in the total activated CD8+ T cells (Fig. 11a). This was
not surprising, because compared to the draining LN, the spleen is a
much larger organ. Thus, the contribution of newly activated CD8+
T cells in response to the vector constitutes a much smaller fraction
than basal level of activation that could be present. Interestingly,
signiﬁcantly fewer cells in the activated CD62Llo CD8+ T
splenocytes from the GM-CSF group had taken up BrdU (Fig. 11b).
This would indicate signiﬁcantly less proliferation of CD8+ T cells in
the GM-CSF expressing group, except we did not see these differences
translate to a decrease in the total activated CD8+ T cell population in
the spleen (Fig. 11a). Thus we cannot rule out other mechanisms suchas cell death that may also contribute to the loss of this group of rep-
licating cells.
Similar analyses were done on CD4+ T cell population (Fig. S3).
There were no signiﬁcant differences in total activated CD4+ T cell
populations in the draining LNs and spleen (Fig. S3a). BrdU incorpora-
tion in these cells indicated no differences in CD4+ T cell proliferation
between the GM-CSF expressing RABV and control (Fig. S3b). Thus
GM-CSF expression does not seem to have an impact on the CD4+ T
cell population. Taken together, these data show that exogenous
GM-CSF expressed by a RABV vaccine vector negatively affects
CD8+ T cell proliferation in the spleen.
Discussion
DCs are potent APCs with well-deﬁned roles in antigen processing
and presentation (Steinman, 2007). Due to the proﬁciency with
which they link the innate and adaptive arms of the immune re-
sponse, they have been incorporated in vaccine research and devel-
opment in order to improve immune responses (Steinman and
Pope, 2002). In this study, we constructed a novel RABV-vaccine con-
struct co-expressing HIV-1 Gag and GM-CSF, which we hypothesized,
would increase the CD8+ T cell response due to recruitment of APCs
in vivo. Such an effect of GM-CSF on the CD8+ T cell response has pre-
viously been shown with VSV (Ramsburg et al., 2005). Instead, we
found that GM-CSF expression by our RABV-based vaccine vector sig-
niﬁcantly reduced the CD8+ T cell responses, whereas the humoral
immune responses were unmodiﬁed.
This diminished CD8+ T cell response was in spite of the presence
of signiﬁcantly more APCs (DCs, macrophages and B cells) in the
BNSP-Gag–GM-CSF immunized mice. Similar ﬁndings have been
reported in a vaccine study using recombinant respiratory syncytial
virus (rRSV), also a single stranded negative sense RNA virus. They
showed that co-expression of GM-CSF led to a four-fold increase in
pulmonary lymphoid and myeloid DCs, and macrophages over the
parent virus (Bukreyev et al., 2001). Despite this increase, the GM-
CSF expressing rRSV induced a lower primary CD8+ T cell response
in mice. They observed that CD8+ T cells from GM-CSF expressing
rRSV induced 14.24% speciﬁc lysis in comparison to 23.05% speciﬁc
lysis by the parent vector, Pb0.02. The authors explained that the re-
duction in the CD8+ T cells was a result of reduced antigenic dose.
They hypothesized that GM-CSF-dependent activation of APCs and
an increase in inﬂammatory cytokines such as IFN-γ reduced replica-
tion of the virus 50-fold (Bukreyev et al., 2001). Unlike this rRSV
study, the diminished CD8+ T cell response to BNSP-Gag–GM-CSF
was not a result of poor viral replication based on similar levels of
replication between BNSP-Gag–IFN(−) and BNSP-Gag–GM-CSF in
vivo, analyzed three days post prime. Furthermore, previous studies
have shown that activation of CD8+ T cells by both replication
competent and single-cycle RABV vaccine vectors is not dose depen-
dent over a range of doses, 104–10 6(100-fold) (Gomme et al.,
2010). These data highlight an important characteristic of RABV as a
vaccine vector, especially when designing vaccines that could be
used in areas where conditions may not be optimal for maintaining
the integrity of the vaccines.
A study using VSV expressing GM-CSF showed an increase in APCs
that were mostly macrophages (Ramsburg et al., 2005). Although
they did not see an increase in the primary CD8+ T cell response,
GM-CSF appeared to enhance the long-term memory and recall
CD8+ T cell responses, which they hypothesized, was due to an in-
crease in antigen presentation in spite of viral attenuation. Similar
to VSV, RABV expressing GM-CSF recruited more macrophages, DCs
and B cells than the controls. However unlike the VSV study, the
memory and recall CD8+ T cell responses were diminished. If we
compare the VSV study to ours, perhaps the main difference we ob-
served was that in general, the RABV vaccine vector recruited signiﬁ-
cantly more DCs than PBS controls, whereas this was not the case for
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CD8+ T cell responses could be DCmediated, as DCs also play a role in
the induction of peripheral tolerance (Steinman et al., 2003). Howev-
er, this mechanism is least likely because we saw signiﬁcantly more
DCs with an activated phenotype after GM-CSF expression compared
to the controls.
An important ﬁnding of this study was the disparate induction of
primary CD8+ T cell responses in draining ILNs and the spleen. The
former showed a trend towards higher numbers of antigen speciﬁc
CD8+ T cells whereas there were consistently signiﬁcantly fewer
numbers in the spleen. Based on the differences observed between
ILNs and the spleen, there was a possibility that GM-CSF expression
altered the distribution of Gag-speciﬁc CD8+ T cell responses. Analy-
sis of memory responses implied that the effect of GM-CSF was long
term in both organs. Furthermore, recall responses after different
routes of challenge with VV-Gag showed persistent effects of GM-
CSF in the spleen. In addition, analysis of PLNs after both i.m. and sub-
cutaneous VV-Gag challenges showed fewer antigen speciﬁc CD8+ T
cells, which might imply that the effect of GM-CSF is not restricted
to the spleen.
With regard to vaccine development, the effect of GM-CSF on long
term memory is important, and based on our experiments it seemed
to have an overall effect of reducing the memory antigen speciﬁc
CD8+ T cells. Despite the signiﬁcant reduction in CD8+ T responses
seen in the GM-CSF group, our study did not eliminate the possibility
that GM-CSF altered the distribution of the CD8+ T cells after prime.
Future studies analyzing the distribution of antigen speciﬁc CD8+
and CD4+ T cells in the primary phase of the response in different or-
gans including non draining LNS, the site of immunization (muscle)
and the liver will be included to rule out differential distribution.
Although GM-CSF has been shown to have adjuvant effects in mice
(Lu et al., 2002; Wen et al., 2010; Yoon et al., 2006; Zhang et al.,
2011), monkey (Loudon et al., 2010) and human studies (Jaffee et
al., 2001; Luiten et al., 2005; Mastrangelo et al., 1999), there is evi-
dence of a counteracting role in immune suppression (Kass et al.,
2000). The disparate effects of GM-CSF partly depend on whether it
is expressed locally at the site of immunization or systemically
(Parmiani et al., 2007). Immunosuppressive effects are more evident
with systemic expression of high dose GM-CSF thought to induce
the differentiation of MSDCs (CD11b+ GR1+ cells) (Seraﬁni et al.,
2004). Our analysis of CD11b+ GR1+ cells in mice immunized with
the RABV vectors, showed no signiﬁcant increase in MSDCs with
GM-CSF expression, suggesting that there might be an alternative
mechanism. It has been shown that regulatory T cells (Tregs) express
the GM-CSF receptor CD116 which can activate them directly leading
to their expansion (Kared et al., 2008). Tregs are known to regulate
proliferation and apoptosis of CD8+ T cell responses (Bronte et al.,
2000; Sakaguchi et al., 2008). Our analysis of the spleen depicted
lower proliferation of activated CD8+ T cells when mice were immu-
nized with the GM-CSF expressing RABV vector. The BrdU analysis did
not rule out cell death because proliferating cells undergoing cell
death could also lead to a reduction in this BrdU+ cells.
More recently, Wen et al. using RABV expressing GM-CSF, showed
that mice immunized with RABV expressing GM-CSF recruited and or
activated DCs and B cells in their blood and draining LNs (Wen et al.,
2010). As a result, the GM-CSF expressing vector stimulated a more
robust humoral immune response than parent vector. Similar to our
studies, they tested their GM-CSF construct in BALB/c mice and saw
an increase in DCs and B cells. However, the immunogenicity studies
in which they saw induction of higher levels of neutralizing anti-
bodies with GM-CSF were done in ICR mice, an outbred strain differ-
ent from the inbred BALB/c strain. The ICR mice were immunized
with 1×106 FFU of experimental and control viruses and their
serum tested 21 days post prime for RABV neutralizing antibodies.
They found that GM-CSF expressing vector had 15.65 IU virus com-
pared to 8.01 IU seen with the parent virus, Pb0.5. Furthermore, thedifferences in VNAs translated to better protection of mice when chal-
lenged with 1×107 FFU CVS-24 (Wen et al., 2010). However, the
group did not report the characteristics of the antibody so it is not
clear whether there were higher titers of antibodies or if there were
differences in antibody subtypes. We saw no differences in the hu-
moral response when mice received 1×105 FFU (i.m.) of BNSP-Gag–
IFN(−) or BNSP-Gag–GM-CSF. In fact, they both stimulated a Th1
dominant immune response. Although Wen et al. tested different
viral titers, they did not publish the results at the lower titers. The
discrepancy in our ﬁndings might be attributed to the viral dose. It
is also possible that the impact of GM-CSF in adjuvanting immune re-
sponses might be dependent on mouse strain.
Considering that GM-CSF is a widely studied adjuvant in human
vaccine trials with the possibility of inclusion in vaccine regimens,
more research is warranted to better understand the interaction of
GM-CSF, antigens and the host's immune response. Furthermore,
going forward this studymay have implications on RABV as a vaccine
vector. Because it indicates that RABV may have a certain trait that
interacts with GM-CSF in BALB/c mice so as to reduce CD8+ T cells.
This may present a target for improvement of the RABV vaccine
vector.
Materials and methods
Mice
6–8 week old female BALB/c mice were purchased from the Na-
tional Institute of Health (NIH). All animal protocols (414G, 414A)
were in accordance with Institutional Animal Care and Use Commit-
tee at Thomas Jefferson University (TJU).
Construction and recovery of infectious virus
GM-CSF was ampliﬁed frommouse spleen cDNA using PCR primer
5′-CCCAAGATCTCGTACGCGAGGAGGATGTGGCTGCAGAA-3′ that con-
tains a BsiWI restriction site and 5′-ACCCCAGCTAGCGAATTCTCA-
GAGCTGGCCTGGGCTTCC-3′, that contains an NheI restriction site.
The PCR product was cut with BSiWI and NheI and cloned into
pSPBN, a plasmid encoding the recombinant RABV vaccine vector
(McGettigan et al., 2003b). The resulting vector was then digested
with SmaI–AfII to obtain a fragment that contained GM-CSF ﬂanked
by SmaI–AfII. This fragment was cloned into a plasmid encoding re-
combinant RABV and HIV-1 Gag. This new cDNA, designated BNSP-
Gag–GM-CSF, was recovered on BSR (BHK-21 clone) cells
transfected with 5 μg cDNA encoding BNSP-Gag–GM-CSF along with
support plasmids encoding T7, RABV-N, RABV-P, RABV-G and RABV-
L (1.5, 2.5, 1.25,1 and 1.25 μg respectively) per 6 well plate (Faul et
al., 2008) using Lipofectamine™ 2000 (Invitrogen) as per manufac-
turer's protocol. The cells were incubated with the transfection re-
agent overnight after which all the media was aspirated off and
replaced with fresh DMEM media containing 5% Fetal Bovine Serum
(FBS) and 1% Penicillin Streptomycin. Infectious virus from the super-
natants was used to infect BSR cells (in a T 175cm2 ﬂask) for 2 h after
which the cells were washed and replenished with serum free Opti-
pro media (Invitrogen). The serum free virus stocks harvested on
day 3 and day 8 post infection were combined and titered on BSR
cells as previously published (Wirblich and Schnell, 2011). BNSP,
BNSP-Gag and BNSP-Gag–IFN(−) were grown as previously
described (Faul et al., 2008; McGettigan et al., 2001).
Multi-step growth curve
The multistep growth curve was done as previously described
with some modiﬁcations (Wirblich and Schnell, 2011). In brief, BSR
cells were infected with BNSP, BNSP-Gag, BNSP-Gag–IFN(−) or
BNSP-Gag–GM-CSF at an MOI=0.01. After 2 h of incubation, the
131C.N. Wanjalla et al. / Virology 426 (2012) 120–133cells were washed twice with phosphate-buffered saline (PBS) to re-
move any virus still present in themedia. The cells were then incubat-
ed in fresh DMEMmedia supplemented with 5% FBS and 1% Penicillin
Streptomycin (4 ml/well of 6-well plate) at 34 °C, 5% CO2 and 300 μl
aliquots of the supernatants collected in 24 h intervals over 4 days.
The viral titers in the supernatants were determined on BSR cells as
above.
Immunization and challenge protocols
Unless otherwise stated, BALB/c mice were primed intramuscularly
(i.m.) with 1×105 foci forming units (FFU) of control or experimental
RABV in 100 μl administered as two injections — 50 μl per hind limb.
For boost and challenge experiments, the mice were rested for at least
30 days. Challenge experiments were performed using 1×106 plaque
forming units (pfu) vaccinia virus expressing HIV-1 Gag (VV-Gag).
This was given in a volume of 300 μl intraperitoneally (i.p.).
Flow cytometry
Cells were stained for ﬂow cytometry as previously published
(Wanjalla et al., 2010). In brief, DC cultures or splenocytes and lym-
phocytes were resuspended in staining buffer containing 2% Bovine
Serum Albumin in PBS (FACS buffer). To prevent non-speciﬁc binding
of antibodies to Fc receptors, cells were incubated with 1.1 μg anti-
CD16/32 (BD Biosciences) per 100 μl FACS buffer for at least 15 min
at room temperature or for 1 h on ice. When tetramer staining was
to be performed, the cells were also incubated with unconjugated
streptavidin in FACS buffer for 45–60 min on ice. This would bind
non-speciﬁcally to T cells and reduce non-speciﬁc binding by the
streptavidin-conjugated tetramer antibody. The cells were then
washed 2 times in FACS buffer and then incubated with
ﬂuorochrome-linked antibodies against surface proteins RABV-N
(Centocor, Inc), PerCP-CD8α, APC-CD11c, PerCP-GR1, FITC-CD11b,
PerCP-F4/80, PerCP-B220, PE-CD86, FITC-CD44, PE-AMQMLKETI tet-
ramer (Becton Dickinson), APC-CD62L, APC-IL-2, PE-IL-6, FITC-IL-10,
PE-IFN-γ, APC-TNF-α (BD Biosciences), PaciﬁcBlue-CD19, and CD40
(eBioscience, Inc). This was done for 20 min at room temperature
after which the cells were washed two times with FACS buffer and
then ﬁxed in BD cytoﬁx, which contains 4% paraformaldehyde. The
cells were further washed twice and resuspended in FACS buffer.
The analyses were done on BD FACS Calibur or BD LSRII machine at
the Kimmel Cancer Center core facility (TJU).
Immunoﬂuorescence
BSR cells were infected with BNSP, BNSP-Gag–IFN(−) or BNSP-
Gag–GM-CSF for 48 h at 37 °C 5% CO2. The ﬁxation and staining
protocol was done as previously published (Gomme et al., 2010). In
brief, cells were ﬁxed in 4% PFA for 20 min at 4 °C. Both HIV-1 Gag
and RABV-N are internal proteins that require permeabilization of
the cells which was done using 0.1% Triton X-100 in PBS. The cells
were blocked with either 10 mM glycine for anti-RABV-N monoclonal
antibody (Centocor) or 5% milk for anti-HIV-1 Gag (anti p24 71–31;
NIH AIDS Research and Reference Reagent Program). Antibody stain-
ing was done at 37 °C for half an hour. Anti-p24 stained cells were
later incubated with a Cy-2 tagged secondary donkey anti-human
IgG (Jackson ImmunoResearch) (Gomme et al., 2010).
IFN- γ ELISpot
Splenocytes or lymphocytes from immunized mice assayed in
triplicate were prepared in 96-well round-bottomed plates at differ-
ent densities for primary (1–1.5 million cells per well) and recall re-
sponses (12,500–25,000 cells per well). One additional well per
sample was included for the no peptide control. The 96-roundbottomed wells were then spun-down on a table-top centrifuge at
250 g for 3 min. The cells were then resuspended 100 μl in splenocyte
media containing costimulatory antibodies: 1 μg/ml CD49d (BD Bio-
sciences) and 1 μg/ml CD28 (BD Biosciences) and 10 g/ml AMQMLK-
ETI — an MHCI-restricted immunodominant HIV-1 Gag peptide used
throughout the study. The no-peptide control wells were resus-
pended in 100 μl splenocyte media. The cells were then transferred
onto the 96-well multiscreen plates. These multiscreen ﬁltration
plates (Millipore) were prepared the night before the experiment.
For IFN-γ, the plates were pre-coated with rat anti-mouse IFN-γ
monoclonal antibody (BD Pharmingen) for at least 2 h at room tem-
perature or overnight. These were then washed three times with
0.25% Tween, followed by three washed with PBS. The plates were in-
cubated with splenocyte media in a cell incubator 37 °C, 5% CO2 for at
least 2 h, after which the cells could be plated. After a 16–22 h incuba-
tion, the cells were washed out with 0.25% Tween in PBS followed by
a water lysis step to get rid of any remnant cells. The plate was then
incubated with 10 μg/ml biotinylated rat anti-mouse IFN-γ mAb
(Pharmingen, CA, 554410) for 2 h at room temperature or overnight
at 4 °C. For the latter, the plate was sealed in paraﬁlm to prevent
evaporation of the antibodies. The plate was further washed with
0.25% Tween in PBS followed by treatment with horseradish
peroxidase-conjugated streptavidin at a dilution of 1:5000 (Jackson
ImmunoResearch). 2 h later, the plate was washed with 0.25%
Tween in PBS, followed by PBS only prior to the development of
spots. Spots were developed after addition of peroxidase substrate
and analyzed using an ImmunoSpot C.T.L reader 5.0.
Bone marrow cell culture
Bone marrow cells were obtained from mice as previously pub-
lished (Wanjalla et al., 2010). Cells were cultured in splenocytes
media with either 10 ng/ml recombinant GM-CSF (Peprotech) or
with UV-treated supernatants from BSR cells infected with either
BNSP-Gag–IFN(−) or BNSP-Gag–GM-CSF 72 h post infection. The
supernatants were used at two different dilutions (1:4, 1:7) and the
bone marrow cells were incubated for 7 days at 37 °C, 5% CO2. Two
washes were performed on days 2 and 4 of the incubation period
with replacement of the GM-CSF either using recombinant protein
as a controls or with supernatants for the test samples (Wanjalla et
al., 2010). At day 7 the cells were harvested and analyzed for expres-
sion of surface molecules, APC-CD11c, PE-CD80, and PE-CD86 (BD
Bioscience) by ﬂow cytometry.
Rabies virus G protein enzyme-linked immunosorbent assay (ELISA)
We measured the amount of GM-CSF secreted by BSR cells
infected with our viral constructs using a GM-CSF ELISA kit
(eBioscience Inc.) as per the manufacturer's protocol. Supernatants
collected from infected cells were UV-treated to inactivate any virus
and then stored at −20 °C until analysis. Anti-RABV G ELISAs were
done as previously published (Gomme et al., 2010).
Antibody avidity assay
This was carried out as previously published (Cenna et al., 2009).
In brief, RABV-G ELISAs were set up as previously published
(Gomme et al., 2010). However, prior to the addition of the HRP
tagged secondary antibody, the plates were treated with 100 μl of in-
creasing concentrations of sodium thiocyanate (NASCN, Sigma Al-
drich) 0, 0.5, 1, 1.5, 2, 2.5 and 3 mmol/l. Note that for the 0 mmol/l
salt concentration, the wells were incubated with distilled water be-
cause the salt solutions were diluted in water. The plates were incu-
bated for 15 min at room temperature and then washed
immediately six times with 0.025% Tween in PBS. The rest of the pro-
tocol proceeded as the RABV-G ELISA described above.
132 C.N. Wanjalla et al. / Virology 426 (2012) 120–133Rapid ﬂuorescent focus inhibition test (RFFIT) assay
Analysis of the virus neutralizing titers was done using RFFIT as-
says as published (Cenna et al., 2009). In brief, sera collected from im-
munized mice were heat inactivated for 30 min at 56 °C to inactivate
complement. The sera were plated in three-fold dilutions in a 96-
well plate to which CVS-11 was added. Serial dilutions of the WHO
anti-RABV antibody standard were included as a control. After 1 h in-
cubation at 37 °C, 5% CO2 the contents of each well were transferred to
a 96-well plate containing 90% conﬂuent NA cells. The plateswere har-
vested 24 h post infection and infectious viruswas quantiﬁed by stain-
ing with an antibody against RABV-N (Centocor, Inc). Calculations of
the virus neutralizing titers were done as published and normalized
using the WHO standard and listed as international units (I.U.).
Bromodeoxyuridine (BrdU) proliferation assay
BALB/c mice were primed on day 0 with 1×105 FFU/mouse BNSP-
Gag–IFN(−) or BNSP-Gag–GM-CSF. PBS mice were included as a
control. 4 days post prime the mice received 2 mg BrdU i.p. on day
three, after which they received 0.8 mg/ml BrdU in water on days
four, ﬁve and six. The spleens and draining LNs were obtained from
the mice on day 7 post prime processed and stained for surface and
BrdU staining using the FITC BrdU ﬂow kit as per the manufacturer's
protocol (BD Pharmingen) for ﬂow cytometry.
Statistics
Data collected were analyzed using the GraphPad Prism versions
4.0 and 5.0, San Diego California USA, www.graphpad.com. One-way
ANOVA with Bonferroni post-test analysis was used where more
than two groups were compared. Signiﬁcant differences in this
case were represented as *Pb0.05, **Pb0.01, ***Pb0.001 and
****Pb0.0001. Student's t-test was used to compare two groups to
each other and represented as two-tailed P value, conﬁdence inter-
val of 95%.
Acknowledgments
The authors thank Matthew Farabaugh from the Kimmel Cancer
Center Flow Cytometry Facility for technical assistance. This work
was supported by a grant from NIH/NIAID to M.J.S. (P01AI082325).
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.virol.2012.01.025.
References
Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M., Oldstone, M.B., 1994. Virus-speciﬁc
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in prima-
ry human immunodeﬁciency virus type 1 infection. J. Virol. 68, 6103–6110.
Brode, S., Macary, P.A., 2004. Cross-presentation: dendritic cells and macrophages bite
off more than they can chew! Immunology 112, 345–351.
Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Seraﬁni, P., Zamboni, P., Restifo, N.P.,
Zanovello, P., 2000. Identiﬁcation of a CD11b(+)/Gr-1(+)/CD31(+) myeloid pro-
genitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838–3846.
Bukreyev, A., Belyakov, I.M., Berzofsky, J.A., Murphy, B.R., Collins, P.L., 2001. Granulo-
cyte–macrophage colony-stimulating factor expressed by recombinant respiratory
syncytial virus attenuates viral replication and increases the level of pulmonary
antigen-presenting cells. J. Virol. 75, 12128–12140.
Burgess, A.W., Camakaris, J., Metcalf, D., 1977. Puriﬁcation and properties of colony-
stimulating factor from mouse lung-conditioned medium. J. Biol. Chem. 252,
1998–2003.
Carlsson, T., Struve, J., 1997. Granulocyte–macrophage colony-stimulating factor given
as an adjuvant to persons not responding to hepatitis B vaccine. Infection 25, 129.
Cenna, J., Hunter, M., Tan, G.S., Papaneri, A.B., Ribka, E.P., Schnell, M.J., Marx, P.A.,
McGettigan, J.P., 2009. Replication-deﬁcient rabies virus-based vaccines are safe
and immunogenic in mice and nonhuman primates. J. Infect. Dis. 200, 1251–1260.Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V.,
Hamada, H., Pardoll, D., Mulligan, R.C., 1993. Vaccination with irradiated tumor
cells engineered to secrete murine granulocyte–macrophage colony-stimulating
factor stimulates potent, speciﬁc, and long-lasting anti-tumor immunity. Proc.
Natl. Acad. Sci. U. S. A. 90, 3539–3543.
Faul, E.J., Wanjalla, C.N., McGettigan, J.P., Schnell, M.J., 2008. Interferon-beta expressed
by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and
decreases pathogenicity. Virology 382, 226–238.
Faul, E.J., Aye, P.P., Papaneri, A.B., Pahar, B., McGettigan, J.P., Schiro, F., Chervoneva, I.,
Monteﬁori, D.C., Lackner, A.A., Schnell, M.J., 2009. Rabies virus-based vaccines
elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus
macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 28,
299–308.
Gomme, E.A., Faul, E.J., Flomenberg, P., McGettigan, J.P., Schnell, M.J., 2010. Characteri-
zation of a single-cycle rabies virus-based vaccine vector. J. Virol. 84, 2820–2831.
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S.,
Steinman, R.M., 1992. Generation of large numbers of dendritic cells from mouse
bone marrow cultures supplemented with granulocyte/macrophage colony-
stimulating factor. J. Exp. Med. 176, 1693–1702.
Iwasaki, A., Medzhitov, R., 2004. Toll-like receptor control of the adaptive immune re-
sponses. Nat. Immunol. 5, 987–995.
Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann,
M., Coleman, J., Grochow, L., Donehower, R.C., Lillemoe, K.D., O'Reilly, S., Abrams,
R.A., Pardoll, D.M., Cameron, J.L., Yeo, C.J., 2001. Novel allogeneic granulocyte–mac-
rophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a
phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145–156.
Janke, M., Peeters, B., de Leeuw, O., Moorman, R., Arnold, A., Fournier, P., Schirrmacher,
V., 2007. Recombinant Newcastle disease virus (NDV) with inserted gene coding
for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 14,
1639–1649.
Jin, X., Bauer, D.E., Tuttleton, S.E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C.E., Safrit, J.T.,
Mittler, J., Weinberger, L., Kostrikis, L.G., Zhang, L., Perelson, A.S., Ho, D.D., 1999.
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immuno-
deﬁciency virus-infected macaques. J. Exp. Med. 189, 991–998.
Kared, H., Leforban, B., Montandon, R., Renand, A., Layseca Espinosa, E., Chatenoud, L.,
Rosenstein, Y., Schneider, E., Dy, M., Zavala, F., 2008. Role of GM-CSF in tolerance
induction by mobilized hematopoietic progenitors. Blood 112, 2575–2578.
Kass, E., Parker, J., Schlom, J., Greiner, J.W., 2000. Comparative studies of the effects of
recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the con-
centration of antigen-presenting cells in regional lymph nodes. Cytokine 12,
960–971.
Kindt, T.J., Goldsby, Richard A., Osborne, Barbara Anne, Kuby, Janis, 2007. Kuby Immu-
nology, SIXTH EDITION ed. Sara Tenney, New York.
Loudon, P.T., Yager, E.J., Lynch, D.T., Narendran, A., Stagnar, C., Franchini, A.M., Fuller,
J.T., White, P.A., Nyuandi, J., Wiley, C.A., Murphey-Corb, M., Fuller, D.H., 2010.
GM-CSF increases mucosal and systemic immunogenicity of an H1N1 inﬂuenza
DNA vaccine administered into the epidermis of non-human primates. PLoS One
5, e11021.
Lu, H., Xing, Z., Brunham, R.C., 2002. GM-CSF transgene-based adjuvant allows the es-
tablishment of protective mucosal immunity following vaccination with inacti-
vated Chlamydia trachomatis. J. Immunol. 169, 6324–6331.
Luiten, R.M., Kueter, E.W., Mooi, W., Gallee, M.P., Rankin, E.M., Gerritsen, W.R., Clift,
S.M., Nooijen, W.J., Weder, P., van de Kasteele, W.F., Sein, J., van den Berk, P.C.,
Nieweg, O.E., Berns, A.M., Spits, H., de Gast, G.C., 2005. Immunogenicity, including
vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor
cells in metastatic melanoma patients. J. Clin. Oncol. 23, 8978–8991.
Mastrangelo, M.J., Maguire Jr., H.C., Eisenlohr, L.C., Laughlin, C.E., Monken, C.E., McCue,
P.A., Kovatich, A.J., Lattime, E.C., 1999. Intratumoral recombinant GM-CSF-
encoding virus as gene therapy in patients with cutaneous melanoma. Cancer
Gene Ther. 6, 409–422.
McGettigan, J.P., Sarma, S., Orenstein, J.M., Pomerantz, R.J., Schnell, M.J., 2001. Expres-
sion and immunogenicity of human immunodeﬁciency virus type 1 Gag expressed
by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 75,
8724–8732.
McGettigan, J.P., Naper, K., Orenstein, J., Koser, M., McKenna, P.M., Schnell, M.J., 2003a.
Functional human immunodeﬁciency virus type 1 (HIV-1) Gag–Pol or HIV-1 Gag–
Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J.
Virol. 77, 10889–10899.
McGettigan, J.P., Pomerantz, R.J., Siler, C.A., McKenna, P.M., Foley, H.D., Dietzschold, B.,
Schnell, M.J., 2003b. Second-generation rabies virus-based vaccine vectors expres-
sing human immunodeﬁciency virus type 1 gag have greatly reduced pathogenic-
ity but are highly immunogenic. J. Virol. 77, 237–244.
McGettigan, J.P., Koser, M.L., McKenna, P.M., Smith, M.E., Marvin, J.M., Eisenlohr, L.C.,
Dietzschold, B., Schnell, M.J., 2006. Enhanced humoral HIV-1-speciﬁc immune re-
sponses generated from recombinant rhabdoviral-based vaccine vectors co-
expressing HIV-1 proteins and IL-2. Virology 344, 363–377.
Mebatsion, T., Schnell, M.J., Cox, J.H., Finke, S., Conzelmann, K.K., 1996. Highly stable ex-
pression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. U. S. A. 93,
7310–7314.
Metcalf, D., 1971. Acute antigen-induced elevation of serum colony stimulating factor
(CFS) levels. Immunology 21, 427–436.
Metcalf, D., 1985. Molecular control of granulocyte and macrophage production. Prog.
Clin. Biol. Res. 191, 323–337.
Metcalf, D., Nicola, N.A., Mifsud, S., Di Rago, L., 1999. Receptor clearance obscures the
magnitude of granulocyte–macrophage colony-stimulating factor responses in
mice to endotoxin or local infections. Blood 93, 1579–1585.
133C.N. Wanjalla et al. / Virology 426 (2012) 120–133Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M.P., Rivoltini, L., 2007. Oppo-
site immune functions of GM-CSF administered as vaccine adjuvant in cancer pa-
tients. Ann. Oncol. 18, 226–232.
Plesa, G., McKenna, P.M., Schnell, M.J., Eisenlohr, L.C., 2006. Immunogenicity of cyto-
pathic and noncytopathic viral vectors. J. Virol. 80, 6259–6266.
Ramsburg, E., Publicover, J., Buonocore, L., Poholek, A., Robek, M., Palin, A., Rose, J.K.,
2005. A vesicular stomatitis virus recombinant expressing granulocyte–macro-
phage colony-stimulating factor induces enhanced T-cell responses and is highly
attenuated for replication in animals. J. Virol. 79, 15043–15053.
Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., 2008. Regulatory T cells and immune
tolerance. Cell 133, 775–787.
Schnell, M.J., McGettigan, J.P., Wirblich, C., Papaneri, A., 2010. The cell biology of rabies
virus: using stealth to reach the brain. Nat. Rev. Microbiol. 8, 51–61.
Seraﬁni, P., Carbley, R., Noonan, K.A., Tan, G., Bronte, V., Borrello, I., 2004. High-dose
granulocyte–macrophage colony-stimulating factor-producing vaccines impair
the immune response through the recruitment of myeloid suppressor cells. Cancer
Res. 64, 6337–6343.
Stanley, E., Lieschke, G.J., Grail, D., Metcalf, D., Hodgson, G., Gall, J.A., Maher, D.W.,
Cebon, J., Sinickas, V., Dunn, A.R., 1994. Granulocyte/macrophage colony-
stimulating factor-deﬁcient mice show no major perturbation of hematopoiesis
but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U. S. A.
91, 5592–5596.
Steinman, R., 2007. Dendritic cells: understanding immunogenicity. Eur. J. Immunol.
37, S53–S60.Steinman, R.M., Pope, M., 2002. Exploiting dendritic cells to improve vaccine efﬁcacy. J.
Clin. Invest. 109, 1519–1526.
Steinman, R.M., Hawiger, D., Nussenzweig, M.C., 2003. Tolerogenic dendritic cells.
Annu. Rev. Immunol. 21, 685–711.
Vasu, C., Dogan, R.N., Holterman, M.J., Prabhakar, B.S., 2003. Selective induction of den-
dritic cells using granulocyte macrophage-colony stimulating factor, but not fms-
like tyrosine kinase receptor 3-ligand, activates thyroglobulin-speciﬁc CD4+/
CD25+ T cells and suppresses experimental autoimmune thyroiditis. J. Immunol.
170, 5511–5522.
Wanjalla, C.N., Faul, E.J., Gomme, E.A., Schnell, M.J., 2010. Dendritic cells infected by re-
combinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic
even in the presence of vector-speciﬁc immunity. Vaccine 29, 130–140.
Wen, Y., Wang, H., Wu, H., Yang, F., Tripp, R.A., Hogan, R.J., Fu, Z.F., 2010. Rabies virus
expressing dendritic cell-activating molecules enhances the innate and adaptive
immune response to vaccination. J. Virol. 85, 1634–1644.
Wirblich, C., Schnell, M.J., 2011. Rabies virus (RV) glycoprotein expression levels are
not critical for pathogenicity of RV. J. Virol. 85, 697–704.
Yoon, H.A., Aleyas, A.G., George, J.A., Park, S.O., Han, Y.W., Lee, J.H., Cho, J.G., Eo, S.K.,
2006. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine
against pseudorabies virus through enhanced immune responses. Microbiol.
Immunol. 50, 83–92.
Zhang, S.N., Choi, I.K., Huang, J.H., Yoo, J.Y., Choi, K.J., Yun, C.O., 2011. Optimizing DC
vaccination by combination with oncolytic adenovirus coexpressing IL-12 and
GM-CSF. Mol. Ther. 19 (8), 1558–1568.
